Associated Papers
FLCN-mutated eosinophilic renal tumors: clinicopathologic and molecular analysis of five cases highlighting morphologic heterogeneity.
Zhao M et al.
Virchows Archiv : an International Journal of Pathology, 2026
Colon adenocarcinoma and Birt-Hogg-Dubé syndrome in a young patient: case report and exploration of pathologic implications.
Jirka GW et al.
Cancer Biology & Therapy, 2023
Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinoma.
Jikuya R et al.
Ebiomedicine, 2023
Birt-Hogg-Dubé Syndrome and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome: An Effective Multidisciplinary Approach to Hereditary Renal Cancer Predisposing Syndromes.
Al-Shinnag M et al.
Frontiers in Oncology, 2021
Lymphoplasmacytic lymphoma in a patient with Birt-Hogg-Dubé syndrome.
Kurata K et al.
International Journal of Hematology, 2020
Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets.
Testa U et al.
Medicines (basel, Switzerland), 2020
Birt-Hogg-Dubé syndrome presenting with spontaneous pneumothorax and extensive pulmonary cysts in the absence of skin lesions or renal pathology.
Kumar K et al.
Bmj Case Reports, 2019
BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes.
Hasumi H et al.
Human Molecular Genetics, 2018
Hereditary kidney cancer syndromes: Genetic disorders driven by alterations in metabolism and epigenome regulation.
Hasumi H et al.
Cancer Science, 2018
H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.
Hasumi H et al.
Human Molecular Genetics, 2017
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.
Hasumi Y et al.
Proceedings of the National Academy of Sciences of the United States of America, 2009
Select a paper to view details